c-Met inhibitor

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

By Sharon Kell|2021-02-15T10:03:32+00:0015 Feb 2021|Drug treatments|

A gene called MET codes for a protein called MET [...]

Comments Off

Clinical trial programme with new c-Met inhibitor for kidney cancer initiated in Australia and New Zealand

By Sharon Kell|2018-09-20T07:55:14+00:0020 Sep 2018|Drug treatments|

CBT Pharmaceuticals (a US and China-based biopharmaceutical company) announced the [...]

Comments Off

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.

Registered charity in England, Wales (1164238), and Scotland (SC051330).

© Copyright Action Kidney Cancer 2021

Links

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org